Injectable magnesium oxychloride cement foam (mocf)-derived scaffold for treating osteoporotic bone defects
US-2024108785-A1 · Apr 4, 2024 · US
US9795709B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9795709-B2 |
| Application number | US-201013515405-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 16, 2010 |
| Priority date | Dec 16, 2009 |
| Publication date | Oct 24, 2017 |
| Grant date | Oct 24, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A composite material having a first phase includes an aluminum oxide proportion of at least 65% by volume and a second phase comprising a zirconium proportion of 10 to 35% by volume. The zirconium is present as zirconium oxide. The aluminum oxide is a ceramic matrix and the zirconium oxide is dispersed therein. From 90 to 99% of the zirconium oxide is present in the tetragonal phase. A chemical stabilizer for stabilizing the tetragonal phase of the zirconium oxide is also present. The total content of chemical stabilizer is <0.2 mol % relative to the zirconium oxide content.
Opening claim text (preview).
It is claimed: 1. A composite material comprising: a first phase, said first phase comprising at least 65% by volume aluminum oxide; a second phase, said second phase comprising 10 to 35% by volume zirconium, wherein said zirconium is present as zirconium oxide, and wherein 90 to 99% of said zirconium oxide is present in a tetragonal phase; and a chemical stabilizer for stabilizing said tetragonal phase of said zirconium oxide; wherein said chemical stabilizer for stabilizing said tetragonal phase of said zirconium oxide is present in a total amount of <0.2 mol % relative to said zirconium oxide content; wherein said aluminum oxide is present as a ceramic matrix; and wherein said zirconium oxide is dispersed in said ceramic matrix. 2. The composite material according to claim 1 , wherein said zirconium oxide is present as particles having a grain size on average of 0.1 to 0.5 μm. 3. A sintered body comprising a sintered composite according to claim 1 . 4. A component comprising a sintered composite according to claim 1 , wherein said component absorbs energy under dynamic load. 5. The component of claim 4 , wherein said component is a medical component. 6. The component of claim 5 , wherein said component is a prosthetic. 7. The component of claim 6 , wherein said component is a hip joint implant or a knee joint implant. 8. The composite material according to claim 1 , wherein said zirconium oxide is present as particles having a grain size on average of 0.15 to 0.25 μm. 9. The composite material according to claim 1 , wherein said chemical stabilizer comprises at least one member selected from the group consisting of Y 2 O 3 , CeO 2 , CaO and MgO.
Calcium oxide or oxide-forming salts thereof, e.g. lime · CPC title
Hot isostatic pressing · CPC title
Magnesium oxides or oxide-forming salts thereof · CPC title
Stabilised zirconias, e.g. YSZ or cerium stabilised zirconia · CPC title
Ceramic or ceramic-like structures, e.g. glasses · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.